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Abstract
Non-insulin adjunct therapies in type 1 diabetes have been proposed as a means of improving glycaemic control and reducing risk
of hypoglycaemia. Evidence to support this approach is, however, scant and few pharmacological agents have proved effective
enough to become part of routine clinical care. Recent short-term Phase II trials and 24 week Phase III trials provide initial
support for the use of sodium–glucose cotransporter (SGLT) inhibitors in type 1 diabetes. Two international, multicentre,
randomised, controlled clinical trials, Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes
(DEPICT-1) and inTandem3, have reported that SGLT inhibition with dapagliflozin and sotagliflozin, respectively, confer
additional benefits in terms of a 5–6 mmol/mol (0.4–0.5%) reduction in HbA1c accompanied by weight loss and reductions in
total daily insulin doses. The reduction in HbA1c does not come with a significantly increased risk of hypoglycaemia but does
carry an increased risk of diabetic ketoacidosis and mycotic infections. These results suggest that SGLT inhibition will have a
place in the management of type 1 diabetes. Longer-term clinical trials (≥52 weeks) and observational cohort studies are needed
to determine any additional benefits or adverse effects of this adjunct therapy and to determine which group of patients may
benefit most from this approach. In addition, use of SGLT inhibitors in routine type 1 diabetes care will require specific patient
and healthcare professional educational packages to ensure patient safety and to minimise risk.
Keywords Clinical trials .Diabetic ketoacidosis .GLP-1 receptor agonist .HbA1c .Hypoglycaemia . Insulin .Review .Sodium–
glucose cotransporter inhibitors . Type 1 diabetes .Weight
Abbreviations
CGM Continuous glucose monitoring
DEPICT-1 Dapagliflozin Evaluation in Patients with
Inadequately Controlled Type 1 Diabetes
DKA Diabetic ketoacidosis
MDI Multi-dose insulin
REMOVAL REducing with MetfOrmin Vascular Adverse
Lesions
SBP Systolic blood pressure
SGLT Sodium–glucose cotransporter
Introduction
Chronic exposure to hyperglycaemia in type 1 diabetes carries
an increased risk of microvascular [1] and macrovascular
disease [2]. Intensive insulin therapy aimed at optimal glucose
control can largely prevent or minimise these complications,
especially when combined with appropriate blood pressure
control and lipid-lowering therapy [1, 2]. Current insulin
delivery systems are limited by peripheral drug delivery and
lack of feedback inhibition. This, together with the impaired
response to hypoglycaemia in type 1 diabetes, means that
intensive insulin therapy is associated with increased glucose
variability, weight gain and severe hypoglycaemia [3–5].
Hence, most individuals with type 1 diabetes do not achieve
recommended glycaemic targets [6, 7] and overall life expec-
tancy is still substantially lower than in the non-diabetic popu-
lation [8]. Meeting the twin challenges of hyperglycaemia
and hypoglycaemia in type 1 diabetes may require addi-
tional adjunct pharmacotherapies to complement insulin
replacement [9].
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Adjunct non-insulin pharmacological
interventions in type 1 diabetes
Initial trials of adjunct therapy in type 1 diabetes were small,
short-term and generally had unimpressive outcomes [9].
Pramlintide, currently licensed only in the USA, was one of
few agents shown to be effective, but its beneficial effects on
HbA1c and weight were small and the risk of hypoglycaemia
was increased [10]. Of the dipeptidyl peptidase-4 inhibitors,
sitagliptin is the most widely studied as adjunct therapy in type
1 diabetes, but no major benefit was seen in three 52 week
RCTs [11–13]. More recently, two large multicentre RCTs,
ADJUNCT ONE (N = 1400) [14] and REMOVAL
(REducing with MetfOrmin Vascular Adverse Lesions; N =
428) [15], examined the effectiveness of the glucagon-like
peptide-1 receptor agonist liraglutide (1.2 mg and 1.8 mg
doses) and metformin, respectively, as adjuncts to insulin
therapy in type 1 diabetes. In ADJUNCT ONE, liraglutide
showed significant benefits over placebo in terms of HbA1c,
weight and total insulin dose reduction. However, the impact
on HbA1c was not impressive (mean 0.15–0.2% reduction)
and the rates of symptomatic hypoglycaemia and
hyperglycaemia with ketosis increased significantly.
Accordingly, Novo Nordisk, the sponsor of the ADJUNCT
trials, did not pursue a label indication for liraglutide in type
1 diabetes. Similarly, despite the frequent off-label use of met-
formin in type 1 diabetes [9, 16], in the REMOVAL study it
failed to significantly reduce carotid intima–media thickness
(the primary endpoint) and early small reductions in HbA1c
and body weight were not sustained [15].
In summary, while the rationale for adjunct therapy in type
1 diabetes is clear, there is little robust evidence to support the
adjunctive use of currently available therapies.
Phase II clinical trials of SGLT inhibition
in type 1 diabetes
Sodium–glucose cotransporters (SGLTs) are found predomi-
nantly in the mucosa of the small intestine (SGLT1) and the
proximal tubules of the kidney (SGLT2 and SGLT1) [13].
SGLT2 inhibition reduces glucose reabsorption in the renal
tubule, leading to increased glucose excretion. SGLT1 inhibi-
tion reduces dietary glucose and galactose absorption in the
intestine and augments the release of gastrointestinal incretins.
Selective SGLT2 inhibitors (empagliflozin, dapagliflozin,
canagliflozin) or dual SGLT1/SGLT2 inhibitors (sotagliflozin)
are therefore an attractive therapeutic proposition for diabetes
because increased urinary glucose excretion will reduce
hyperglycaemia and, through loss of energy (each gram of
glucose lost is equivalent to 16.7 kJ [4 cal]), facilitate weight
loss [17]. While there is an obvious place for such a therapy in
type 2 diabetes, pre-clinical research in rodent models also
suggest that these agents may be beneficial as an adjunct
therapy in type 1 diabetes (e.g. [18, 19]).
In an open-label, proof-of-concept trial in 40 young adults
with long-duration type 1 diabetes, Perkins et al reported on
the effects of empagliflozin 25 mg once daily for 8 weeks.
Participants were asked to reduce prandial and basal insulin
by 30% on initiation of treatment [20], with further dose ad-
justments being made based on capillary glucose measures.
Empagliflozin co-therapy reduced HbA1c by 4 ± 5 mmol/mol
(0.3 ± 0.4%; mean ± SD) and total daily insulin requirements
were decreased, largely as a result of a reduction in basal
insulin (from 25.7 ± 10.6 to 19.5 ± 7.9 U/day, p < 0.0001)
[20]. Mean body weight also decreased (from 72.6 ± 12.7 to
70.0 ± 12.3 kg, p < 0.0001) and, despite the fall in HbA1c,
symptomatic hypoglycaemia <3.0 mmol/l and all
hypoglycaemia <3.9 mmol/l measured using continuous glu-
cose monitoring (CGM) were less frequent compared with
baseline. Two participants withdrew early because of diabetic
ketoacidosis (DKA) (associated with severe gastroenteritis in
one and pump failure in the other).
In a placebo-controlled, double-blind, parallel-group study
using empagliflozin 2.5 mg, 10 mg or 25 mg daily with insulin
for 4 weeks, Pieber et al [21] found benefits in terms of HbA1c
(4–5 mmol/mol [0.4%] reduction), total insulin dose (0.07–
0.09 U/kg reduction) and weight (1.5–1.9 kg reduction) (all p
< 0.05). Similarly, Henry et al randomly assigned 70 adults with
type 1 diabetes (HbA1c 53–86 mmol/mol [7–10%]), stabilised
on insulin, to receive dapagliflozin (1, 2.5, 5 or 10 mg) or
placebo over 2 weeks [22]. Insulin doses were not proactively
reduced but were adjusted based on capillary blood glucose for
safety. Dapagliflozin increased glucosuria dose-dependently,
with the highest dose (10 mg) resulting in a urinary glucose
excretion of 88 g/24 h (95%CI 55, 121) [22]. This dose reduced
24 h average glucose (−2.29 mmol/l [95% CI −3.71, −0.87])
and mean amplitude of glycaemic excursion (−3.77 mmol/l
[95% CI −6.09, −1.45]), both assessed by CGM. Total daily
insulin dose was reduced by 16.2% (95% CI 0.5, 29.4) [22].
An 18 week, double-blind, Phase II randomised study in-
volving 315 adults with long-duration type 1 diabetes assessed
the effect of canagliflozin 100 mg or 300 mg daily vs placebo
as adjunct therapy [23]. Participants initially down-titrated
insulin doses by 10–20% (based on baseline HbA1c), followed
by dose adjustments according to capillary blood glucose.
Significant improvements in the following variables were pro-
duced by canagliflozin 100 mg and 300 mg, respectively (pla-
cebo-subtracted least mean squares differences from base-
line): HbA1c (mean change −3.2 mmol/mol [−0.3%] and −
2.7 mmol/mol [−0.3%]); body weight (mean change −3.4%
and −5.3%) and total insulin dose (absolute mean change in
total insulin dose −4.1 U/day [−8.9%] and −7.6 U/day
[−12.9%]). The latter was largely driven by reductions in basal
insulin. In this trial, DKAwas experienced by 5.1% and 9.4%
of the participants receiving canagliflozin 100 mg and
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300mg, respectively, and by none in the placebo arm. Rates of
hypoglycaemia were broadly similar across all groups, al-
though more episodes of severe hypoglycaemia occurred with
canagliflozin 300 mg [23]. Based on these findings, further
development of the programme for canagliflozin in type 1
diabetes was stopped.
Finally, in a 4 week randomised, placebo-controlled,
double-blind trial in 33 adults with long-duration type 1 dia-
betes, Sands et al [24] studied the effect of the dual SGLT1/2
inhibitor sotagliflozin. Compared with placebo, HbA1c
decreased by 5.3 mmol/mol (0.5%) (p ≤ 0.01) from baseline,
as did total insulin daily dose (approximately 15%; p < 0.05).
In contrast to selective SGLT2 inhibitors, this dual inhibitor
was primarily associated with reduced bolus insulin (−26%, p
< 0.01). Post-meal AUC for glucose and mean amplitude of
glycaemic excursion were also significantly reduced, as was
body weight (−1.7 kg vs −0.5 kg, p < 0.01). There was no
increase in the rate of hypoglycaemia, although two partici-
pants experienced DKA, possibly due to pump failure [24].
Phase III clinical trials with SGLT inhibitors
in type 1 diabetes
The first two Phase III trials of SGLT inhibitors in type 1
diabetes were published in September 2017. In inTandem3
[25], a 24 week double-blind, placebo-controlled RCT, 1402
people with type 1 diabetes were randomised to receive either
sotagliflozin (400 mg/day) or placebo after a 2 week single-
blind run-in period (Table 1). Based on lessons learned from
the Phase II studies, participants were instructed to reduce
meal-time insulin by 30% with the first dose of study drug
and then subsequently adjust insulin based on capillary blood
glucose. Participants received information on the detection
and treatment of DKA and were provided with blood ketone
meters. The cohorts were well-matched at baseline and were
mostly (88%) white adults (aged 42 ± 14 years) with long-
duration type 1 diabetes (20 ± 12 years) and an average base-
line HbA1c of 66 ± 10 mmol/mol (8.2 ± 0.9%) [21]. Sixty per
cent of the participants were on multi-dose insulin (MDI) and
40% were on insulin-pump therapy. The pre-specified com-
posite endpoint (HbA1c <53 mmol/mol [7.0%] at week 24,
with no episodes of severe hypoglycaemia or DKA) was
achieved in significantly more participants taking sotagliflozin
than placebo (28.6% vs 15.2% [95% CI 9.0, 17.8], p < 0.001)
(Table 2). In the whole-group analysis, from baseline to week
24 there was a greater change in HbA1c with sotagliflozin
(difference −6 mmol/mol [−0.5%], p < 0.001) plus a greater
reduction in body weight (difference −2.98 kg, p < 0.001) and
a reduction in placebo-corrected alterations in the mean daily
total, bolus and basal doses of insulin (difference −5.3 U/day
[−9.7%], −2.8 U/day [−12.3%] and −2.6 U/day [−9.9%], res-
pectively, p < 0.001 for all comparisons). In participants with a
baseline systolic blood pressure (SBP) of >130 mmHg, the
reduction in SBP by week 16 was greater with sotagliflozin
(difference −3.5 mmHg, p = 0.002 vs placebo) (Table 2).
Sotagliflozin 400 mg daily was relatively well tolerated com-
pared with placebo (overall rate of any adverse event was 52–
55%), although serious adverse events were more common
with sotagliflozin (48 participants [6.9%] vs 23 [3.3%])
(Table 3). Documented hypoglycaemia and hypoglycaemia
event rates were similar in both groups, although
sotagliflozin-treated participants had a significantly lower
event rate of hypoglycaemia <3.1 mmol/l. As expected,
general mycotic infections and diarrhoea occurred more fre-
quently with sotagliflozin vs placebo and a greater proportion
of participants experienced one or more episodes of DKA
(3.0% vs 0.6%) [21].
The 24 week data from two further ongoing clinical trials
(inTandem1 and inTandem2) have been published as abstracts
[26, 27] (Tables 1–3). Placebo-adjusted effects of sotagliflozin
200 mg and 400 mg in these two RCTs after 24 weeks were
similar to those reported in inTandem3.
The second Phase III trial was the Dapagliflozin
Evaluation in Patients with Inadequately Controlled Type
1 Diabetes (DEPICT-1) trial [28], a double-blind, parallel-
controlled, three-arm, 24 week study in 833 individuals
with type 1 diabetes, in which participants were
randomised to receive dapagliflozin 5 mg or 10 mg or
placebo (Table 1) after a run-in period of 8 weeks to opti-
mise glycaemic control. Participants were asked to reduce
both basal and bolus insulin by up to 20% on the day of
study drug initiation and to adjust subsequent doses based
on self-monitoring of blood glucose four to six times daily.
Two periods (each lasting 2 weeks) of blinded CGM were
also included. Participants received education on DKA and
were provided with blood ketone meters. As in inTandem3,
most participants were white, with a mean age of 42.5
(±13.9) years and a duration of type 1 diabetes of 20.3
(±11.8) years (Table 1) [28]. In this trial, the addition of
dapagliflozin (5 mg or 10 mg) vs placebo to type 1 diabetes
therapy resulted in a significant reduction HbA1c (mean
change from baseline at week 24–5 mmol/mol [−0·42%]
[95% CI −0·56, −0·28] and −4 mmol/mol [−0·45%] [95%
CI −0·58, −0·31] for dapagliflozin 5 mg and 10 mg, respec-
tively, both p < 0.0001 vs placebo) (Table 2). This im-
provement in HbA1c was accompanied by significant re-
ductions in body weight (mean change at week 24 was
−2.96% [95% CI −3.63, −2.28] and −3.72% [95% CI
−4.38, −3.05] for dapagliflozin 5 and 10 mg, respectively,
both p < 0.001 vs placebo) and total daily insulin dose
(mean difference −8.8% [95% CI −12.6, −4.9] and
−13.2% [95% CI −16.8, −9.4] for dapagliflozin 5 mg and
10 mg, respectively, p < 0.001 vs placebo). The proportion-
al reductions seen for basal and bolus insulin doses indi-
vidually were similar in percentage to the total insulin dose
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reduction for each of the dapagliflozin doses. CGM re-
vealed modest but significant reductions in glucose vari-
ability with both doses of dapagliflozin. For instance, the
time spent in the target glucose range (>3.9 mmol/l to
<10.0 mmol/l) was increased from 43.2 ± 12.4% to 52.3
± 14.8% (p < 0.05) after 24 weeks of dapagliflozin 10 mg.
Again, adverse events were not uncommon, with more
genital infections occurring with dapagliflozin vs placebo
(Table 3). Hypoglycaemia (all categories) did not occur
more frequently with dapagliflozin. DKA was infrequent
in all groups (1–2%) and was not increased significantly by
dapagliflozin [28]. However, adjudication of suspected
DKA differed between the DEPICT-1 and inTandem3 trials
and rates of DKA would have been similar had both trials
adopted the same criteria (2.5% increase with treatment vs
placebo groups) [29].
Summary
Most people with type 1 diabetes do not achieve recommen-
ded glycaemic targets. Adjunct therapy may complement in-
sulin replacement and enable more people to achieve their
glycaemic goals but there has been limited evidence to support
this approach. Two recent RCTs, inTandem3 and DEPICT-1,
suggest that SGLT inhibition may prove to be a viable and
effective adjunct therapy in type 1 diabetes [25, 28].
Considering the Phase II and III trials together, on average,
addition of SGLT inhibitors to insulin replacement in type 1
diabetes resulted in a 5–6 mmol/mol (0.4–0.5%) reduction in
HbA1c, a 3–4 kg weight loss and a 10–15% reduction in total
daily insulin dose. The glucose-lowering effect of SGLT in-
hibitors is insulin independent and glucose dependent and is
accompanied by reduced glucose variability. Hypoglycaemia
rates are not increased by SGLT inhibition but there is an
associated increased risk of DKA.
DKA seems to occur more frequently in pump-treated pa-
tients; the use of rapid-acting insulin alone in pumps means there
is no basal insulin back-up as inMDI treatment. An elegant study
by Patel et al [30] suggests that the increased risk of DKA is
predominantly due to the failure of type 1 diabetes patients on
SGLTi to promptly recognise early metabolic decompensation,
which occurs at lower than usual glucose levels, rather than being
due to any acceleration in the rate of ketogenesis following the
interruption of basal insulin infusion. Most healthcare organisa-
tions advocate blood ketone testing if capillary glucose is
>16.7 mmol/l (<300 mg/dl) or persistently >13 mmol/l
(235 mg/dl) and an individual is feeling unwell. However,
Table 3 Number of major adverse outcomes of interest reported in published Phase III studies involving SGLT inhibitor adjunct therapy in type 1
diabetes
Adverse event of special interest Dapagliflozin Sotagliflozin
DEPICT-1a InTandem1a InTandem2a InTandem3
Genital infection PBO: 7 (3%)
DAPA 5 mg: 34 (12%)
DAPA 10 mg: 33 (11%)
PBO 8 (3.0%)
SOTA 200 mg: 16 (6.1%)
SOTA 400 mg: 27 (10.3%)
PBO 4 (1.6%)
SOTA 200 mg: 19 (7.3%)
SOTA 400 mg: 20 (7.6%)
PBO: 15 (2.1%)
SOTA 400 mg: 45 (6.4%)
Diarrhoea Not reported PBO: 14 (5.2%)
SOTA 200 mg: 17 (6.5%)
SOTA 400 mg: 26 (9.9%)
PBO: 8 (3.1%)
SOTA 200 mg: 10 (3.8%)
SOTA 400 mg: 15 (5.7%)
PBO: 16 (2.3%)
SOTA 400 mg: 29 (4.1%)
Serious adverse eventsb PBO: 15 (6%)
DAPA 5 mg: 19 (7%)
DAPA 10 mg: 24 (8%)
PBO: 3.4%
SOTA 200 mg: 3.8%
SOTA 400 mg: 6.9%
PBO: 3.5%
SOTA 200 mg: 4.2%
SOTA 400 mg: 4.2%
PBO: 23 (3.3%)
SOTA 400 mg: 48 (6.9%)
Deathsb PBO: 1 (<1%)
DAPA 5 mg: 0
DAPA 10 mg: 0
PBO 0
SOTA 200 mg: 0
SOTA 400 mg: 0
PBO 2
SOTA 200 mg: 0
SOTA 400 mg: 0
PBO: 2
SOTA 400 mg: 1
Severe hypoglycaemia PBO: 19 (7%)
DAPA 5 mg: 21 (8%)
DAPA 10 mg: 16 (6%)
PBO: 18 (7%)
SOTA 200 mg: 11 (4%)
SOTA 400 mg: 12 (5%)
PBO: 7 (3%)
SOTA 200 mg: 10 (4%)
SOTA 400 mg: 6 (2%)
PBO: 17 (2%)
SOTA 400 mg: 21 (3%)
DKA PBO: 3 (1%)
DAPA 5 mg: 4 (2%)
DAPA 10 mg: 5 (2%)
PBO: 0 (0%)
SOTA 200 mg 3 (1%)
SOTA 400 mg: 8 (3%)
PBO: 0 (0%)
SOTA 200 mg: 2 (1%)
SOTA 400 mg: 4 (2%)
PBO: 4 (1%)
SOTA 400 mg: 21 (3%)
DKA on CSII Not reported PBO: 0 (0%)
SOTA 200 mg: 2 (1%)
SOTA 400 mg: 6 (4%)
PBO: 0 (0%)
SOTA 200 mg: 0 (0%)
SOTA 400 mg: 3 (5%)
PBO: 2 (1%)
SOTA 400 mg: 12 (4%)
DKA on MDI Not reported PBO: 0 (0%)
SOTA 200 mg: 1 (1%)
SOTA 400 mg: 2 (2%)
PBO: 0 (0%)
SOTA 200 mg: 2 (1%)
SOTA 400 mg: 1 (1%)
PBO: 2 (1%)
SOTA 400 mg: 9 (3%)
a This table shows 24 week data from DEPICT, inTandem1 and inTandem2
bWhere values are not presented as n (%), these data were not available
CSII, continuous subcutaneous insulin infusion (pump); DAPA, dapagliflozin; PBO, placebo; SH, severe hypoglycaemia; SOTA, sotagliflozin
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capillary glucose may not rise above 11–12 mmol/l (200–
215 mg/dl) despite significant ketosis in individuals with type 1
diabetes receiving SGLT inhibitor treatment [30]. Education of
patients concerning the risk of DKA at lower than expected
glucose levels is therefore crucial, together with advice on sick-
day rules and routine provision of a blood ketonemeter (see Text
box). Clinicians should consider whether it is safe to prescribe
SGLT2 inhibitors for individuals who are poorly compliant,
whose blood glucose is poorly controlled (HbA1c >75 mmol/
mol [9%]) and who are most at risk for hospitalisation from
DKA [31]. It may also be advisable to limit SGLT inhibition to
those onMDI rather than insulin pump, unless steps can be taken
to minimise the risk of pump failure, which would result in
abrupt discontinuation of insulin. In addition, using the lowest
available dose of SGLT inhibitor may reduce the risks of DKA
and other adverse events. Education of patients should include
revision of insulin:carbohydrate ratios for calculating bolus insu-
lin, perhaps by accounting for predicted glucose loss in the urine,
and to ensure total insulin dose (especially basal) is not reduced
by more than 10–15%.
It remains to be clarified whether dual SGLT1/2 inhibition,
which in the short-term appears to have a greater effect on
postprandial glucose control, confers additional benefits in terms
of HbA1c or other outcomes over the longer term. Upcoming
results from 52 week RCT trials (DEPICT-2, inTandem1,
inTandem2, Empagliflozin as Adjunctive to inSulin thErapy
Over 52 Weeks in Patients with Type 1 Diabetes Mellitus
[EASE-2]) will help to determine whether SGLT inhibitor
adjunct therapy has sustained benefits in terms of HbA1c, weight
and total insulin dose reduction and determine its impact on rates
of DKA and severe hypoglycaemia. Data on long-term clinical
efficacy, safety (especially less-common adverse events), surviv-
al, health-related quality of life, patient-reported outcomes and
resource requirements will require longer-term observational co-
hort studies. Future trials might determine whether the beneficial
effects of SGLT inhibition on blood pressure [25] and arterial
stiffness [32] translate into improved cardiovascular outcomes
(still a major cause of increased morbidity and mortality in type
1 diabetes [8]), whether SGLT inhibitors have a reno-protective
effect in type 1 diabetes (as in type 2 diabetes [33]) and does dual
SGLT1/2 inhibition have additional benefits in those with
impaired renal functionbecause of the reduction in gastrointestinal
glucose uptake. Alternatively, will early animal data showing
these compounds can increase renal excretion of calcium [34],
and results from CANVAS indicating higher fractures rates in
participantswith type2diabetes takingcanagliflozin [35], translate
into an already increased risk of bone fractures in type 1 diabetes?
Taken together, early data are promising but further re-
search is needed to define clearly the cohort of people with
type 1 diabetes who will benefit most from SGLT inhibitor co-
prescription as well as to obtain more data on safety and per-
sistence of benefit in the longer term. SGLT inhibitors are not
currently approved by the US Food and Drug Administration
or the European Medicines Agency for use in type 1 diabetes
but they may become a therapeutic option in the future.
Education of patients and healthcare professionals will be of
paramount importance if SGLT inhibitors are to be introduced
safely into routine clinical care of type 1 diabetes.
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Not recommended for poorly compliant patients with 
HbA
1c
 >75 mmol/mol (9%) and history of DKA
Consider increased DKA risk in patients on insulin-
pump therapy
Use lowest available dose of SGLT inhibitor 
required to achieve clinical benefit
Reduce prandial insulin by 10–20% initially and 
adjust doses of prandial and basal insulin based on 
frequent pre- and postprandial glucose monitoring
Reassess insulin:carbohydrate ratios once estab-
lished on SGLT inhibitor
Provide blood ketone meter and advise on DKA 
diagnosis and management
Advise blood ketone testing if patient is feeling sick 
and blood glucose >9 mmol/l 
Advise stopping SGLT inhibitor during intercurrent 
illness or conditions where there is fluid loss or 
reduced fluid intake
Advise about increased risk of genital mycotic 
infections and/or diarrhoea
Recommendations for patients with 
type 1 diabetes initiated on SGLT inhibitor 
adjunct therapy
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